BPC-157
Synthetic 15-amino-acid research peptide
Synthetic 15-amino-acid peptide with extensive animal research in tissue-repair and gastrointestinal models but very limited human evidence.
Reference dose
250–500 mcg daily
Source-specific educational reference, not an individualized recommendation.
Reference schedule
Daily · 4–6 weeks
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
Peptide length
15 amino acids
A synthetic research peptide commonly called BPC-157.
Evidence base
Mostly animal studies
Human evidence remains sparse.
Human safety pilot
2 participants
A 2025 IV pilot was far too small to establish broad safety or efficacy.
Regulatory status
Not FDA approved
FDA reviewed BPC-157-related substances for compounding policy in 2026.
What it is
BPC-157 is a synthetic 15-amino-acid peptide that has been investigated extensively in animal models of tissue injury, gastrointestinal damage and repair.
It is widely discussed in peptide and sports-recovery communities, but the maturity of the human evidence is much lower than its popularity suggests.
Research focus
How it works
BPC-157 has been studied across animal and laboratory models involving tissue repair, angiogenic signalling, nitric-oxide pathways, inflammation and gastrointestinal protection. A single unifying human mechanism has not been clinically established.
Important context
BPC-157 is one of the clearest examples of why preclinical promise and human evidence must be separated. The animal literature is broad, while published human data remain extremely small.
What it is studied for
Musculoskeletal research examines tendon, ligament, muscle and bone-related recovery pathways.
Gastrointestinal research examines protective and repair effects in ulcer, intestinal injury and inflammatory models.
Mechanistic studies explore vascular signalling, nitric-oxide systems, angiogenesis and other processes that could influence tissue repair.
More contextWhy BPC-157 is popular despite the evidence gapSee the deeper context, evidence details and practical distinctions behind this profile.
Animal studies have reported effects across tendon, ligament, muscle, wound, vascular and gastrointestinal models. That breadth has made BPC-157 popular in recovery communities.
The problem is translation: a large preclinical literature does not establish a clinically effective human dose, route, cycle or long-term safety profile.
- A 2025 published pilot evaluated intravenous BPC-157 in only two adults and assessed short-term tolerability rather than injury-healing efficacy.
- A 2025 systematic review in orthopaedic sports medicine found the evidence base was dominated by animal studies.
- In July 2026 FDA brought BPC-157 free base and acetate to its Pharmacy Compounding Advisory Committee as part of the 503A Bulks List review and proposed that they not be included.
- FDA adverse-event material discussed reports involving compounded BPC-157, but spontaneous reports cannot by themselves establish causation.
Why people are interested
What makes BPC-157 worth researching.
Mostly animal research
Tendon & ligament models
Animal studies have explored tendon-to-bone healing, ligament injury and other connective-tissue repair models, which drives much of the recovery interest around BPC-157.
Preclinical
Gastrointestinal research
A substantial preclinical literature examines gastric injury, intestinal damage and protective mechanisms in animal models.
Mechanistic / preclinical
Vascular & repair signalling
Research has explored angiogenic, nitric-oxide and vascular pathways that may interact with wound and tissue repair.
Very limited human data
Human evidence gap
Published human work remains far too limited to support the certainty often implied by online recovery protocols.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
Systematic review · mostly preclinical
Orthopaedic literature
Recent review literature identifies substantial animal work but little high-quality clinical evidence for musculoskeletal use in humans.
Human · n=2 · safety only
Human IV pilot
A 2025 pilot administered intravenous BPC-157 to two adults and reported no short-term adverse effects in the measured parameters. It was not an efficacy trial and cannot establish general safety.
Regulatory evaluation
FDA compounding review
FDA evaluated BPC-157-related bulk substances in 2026 and proposed that BPC-157 free base and acetate not be included on the 503A Bulks List.
Not clinically validated
Popular injection protocols
Commonly circulated subcutaneous doses and cycles are not supported by an approved label or robust controlled human dose-finding programme.
Human research
Published human evidence is extremely limited. A 2025 pilot study included only two adults who received intravenous BPC-157 and reported no short-term adverse effects in the measured laboratory and vital-sign parameters.
That two-person study assessed short-term tolerability, not whether BPC-157 heals tendon, ligament, gut or other injuries in humans.
Recent systematic-review literature continues to describe the musculoskeletal evidence base as being dominated by preclinical studies rather than controlled human outcome trials.
Preclinical research
Animal studies have reported effects across tendon, ligament, muscle, wound and gastrointestinal injury models.
Laboratory and animal work has explored angiogenesis, nitric-oxide signalling, vascular responses and inflammatory pathways as possible mechanisms.
The breadth of preclinical findings is scientifically interesting, but it does not by itself establish human efficacy, optimal route, dose or long-term safety.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
250–500 mcg daily
Daily · 4–6 weeks
The 250–500 mcg daily range is a Pep Report research reference carried through from the original dosing library. It should be read alongside the limited human evidence described on this profile.
Calculator connection
Choose the calculator that matches the actual formulation. The calculator converts numbers you already know; it does not choose the target amount.
For a research vial, concentration depends on both total peptide amount and reconstitution volume. Correct arithmetic does not resolve the larger uncertainty around human dosing and product quality.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Rule of thumb only: BPC-157 does not have an approved finished-drug label that defines one standard storage protocol. Supplier instructions should be treated as formulation-specific rather than as a universal property of BPC-157.
Vial rule of thumb
For a BPC-157 vial, separate dry from reconstituted storage. Keep moisture, heat and unnecessary handling to a minimum, then use the exact temperature and beyond-use data supplied for that formulation rather than a generic 'X weeks in the fridge' rule.
Known data
For BPC-157, the strongest storage data comes from limited formulation literature summarized in FDA's 2026 review rather than from an approved product label. FDA cites reports that lyophilized BPC-157 free base can retain stability for a limited period at room temperature and that colder, desiccated storage may improve longer-term stability.
For BPC-157, the same FDA review cites solution-stability reports at refrigerated and frozen temperatures, but it immediately emphasizes that peptide stability is highly sensitive to formulation, pH, temperature, concentration, impurities and excipients.
Formulation context
For BPC-157, formulation context matters because a dry lyophilized vial and a reconstituted solution are different stability states. Once liquid is added, the diluent, pH, preservative system, concentration, container and handling frequency become part of the stability question.
For BPC-157, supplier-specific testing may support a particular product's storage window, but that evidence cannot automatically be transferred to another salt, concentration, vial or preparation process.
What is not established
For BPC-157, what remains unestablished is one regulator-validated post-reconstitution lifetime, freeze-thaw rule, room-temperature window or injectable shelf life that applies to every product sold under the name.
For BPC-157, the reported stability ranges in the literature are useful context, not a universal instruction. The exact finished formulation still needs its own stability evidence.
Sources
The sources below support the product-specific storage distinctions above.
Practical reference
Formats
Vial / injectable research formats
Reconstitution & units
Adding liquid changes concentration, not the total amount of peptide in the vial.
There is no FDA-approved BPC-157 reconstitution protocol or human dosing label.
mg and mcg describe peptide amount; mL and U-100 syringe units describe liquid volume.
The vial calculator performs concentration arithmetic only. It does not establish a clinically appropriate BPC-157 dose.
Safety, status & open questionsOpen the practical cautionsBPC-157 is not an FDA-approved drug. Human evidence is too limited to treat animal repair findings or popular peptide protocols as established clinical therapy.
Open questions
There is no well-established human dose-response relationship for the popular recovery uses of BPC-157.
Long-term human safety, pharmacokinetics and clinically meaningful injury outcomes remain inadequately characterized.
Different salts, formulations, routes and supplier quality can introduce additional uncertainty beyond the peptide itself.
Regulatory notes
BPC-157 is not an FDA-approved drug.
In July 2026 FDA presented BPC-157 free base and BPC-157 acetate to the Pharmacy Compounding Advisory Committee for 503A Bulks List consideration and proposed that they not be included.
FDA has also emphasized that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing.
Practical notes
Human safety data are too limited to define the full adverse-effect profile or long-term risk.
Compounded or research injectable products add sterility, identity, purity and concentration risks.
Spontaneous adverse-event reports discussed by FDA include injection-site and systemic events, but such reports can be confounded and do not prove causation.
Common mistakes
Treating animal healing results as if the same outcomes were established in humans.
Calling a two-person short-term safety pilot proof that BPC-157 is broadly safe.
Using a popular online dose as though it came from an approved human dose-finding programme.
Confusing accurate vial arithmetic with evidence that a target dose is appropriate.
Common questions
Does BPC-157 have human research?
Yes, but very little. A 2025 IV pilot involved only two adults and assessed short-term tolerability, not whether BPC-157 improves injury recovery.
Is BPC-157 FDA approved?
No. It is not an FDA-approved drug.
Why is BPC-157 associated with tendon and gut recovery?
Those are major themes in the animal and laboratory literature. The direct controlled human evidence is much less developed.
Why is there no validated dose on this profile?
Because popular human protocols are not supported by an FDA-approved label or robust controlled human dose-finding evidence.
Related peptides & blends
TB-500
Synthetic thymosin-beta-4-related fragment researched for wound and tissue-repair biology, with no established human clinical evidence for the fragment itself.
Open reference →BPC-157 / TB-500 (Wolverine)
Research blend name for BPC-157 + TB-500; one 2026 rat tendon study tested the combination directly, but no controlled human blend trial has established efficacy or dosing.
Open reference →References
Emerging Use of BPC-157 in Orthopaedic Sports Medicine — systematic review
PMC / peer-reviewed literature · 2025
Safety of intravenous BPC157 in humans — two-person pilot study
PubMed · 2025
FDA July 2026 PCAC meeting — BPC-157 and other bulk substances
U.S. FDA · 2026
FDA briefing — BPC-157-related bulk drug substances
U.S. FDA · 2026
FDA — understanding the risks of compounded drugs
U.S. FDA · 2026